Plain-English translation of NCT05790213 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination approach to prostate cancer treatment: first giving patients androgen deprivation therapy (a hormone-blocking treatment), followed by focal ablation (a surgical procedure that removes only the cancerous area of the prostate rather than the whole gland). Researchers want to know whether this combined approach is safe and works well for men with intermediate-risk prostate cancer.
Standard prostate cancer treatment often removes or treats the entire prostate, which can cause side effects like urinary and sexual problems. This trial explores whether treating only the cancerous area while using hormone therapy might control cancer effectively while preserving quality of life.
You likely qualify if…
You likely don't qualify if…
You would first receive hormone therapy (androgen deprivation therapy) to slow cancer growth. After this initial treatment phase, you would undergo a focal ablation procedure — a surgery performed under general anesthesia that uses imaging to target and remove only the cancerous portion of your prostate. Your doctor will monitor you closely with visits and imaging studies to track how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States